## Revman Plots: Ibuprofen

### Pain

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Std. Mean Difference</th>
<th>SE</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith 1995</td>
<td>0.77</td>
<td>0.36</td>
<td>10</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td>0.36</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Test for overall effect: Z = 2.14 (P = 0.03)
**Quality assessment**

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>Ibuprofen</th>
<th>Control</th>
<th>Relative (95% CI)</th>
<th>Absolute</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>randomised trials</td>
<td>no serious risk of bias</td>
<td>no serious inconsistency</td>
<td>very serious</td>
<td>serious ²</td>
<td>none</td>
<td>10</td>
<td>10</td>
<td>SMD 0.77 higher (0.06 to 1.48 higher) ¹</td>
<td>⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ</td>
<td>CRITICAL</td>
<td></td>
</tr>
</tbody>
</table>

**Pain** (measured with: validated tool (Visual Analog Scale, 0-100); Better indicated by lower values)

- No of patients: 10
- Effect: SMD 0.77 higher (0.06 to 1.48 higher) ¹
- Quality: ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ ⊕ΟΟΟΟ
- Importance: CRITICAL

**Fear, Distress, Safety, Vaccine Compliance, Preference, Satisfaction** (assessed with: no data were identified for this important outcome)

- No of patients: -
- Effect: -
- Quality: -
- Importance: IMPORTANT

¹ Cross-over trial
² Includes adults undergoing venipuncture; ibuprofen 5% cream administered topically; comparison group was lidocaine-prilocaine 5% cream
³ Sample size was below the recommended optimum information size (OIS) of 400 for an effect size of 0.2.